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Abstract: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune inflammatory
disease with genomic and non-genomic contributions to risk. We hypothesize that epigenetic
factors are a significant contributor to SLE risk and may be informative for identifying pathogenic
mechanisms and therapeutic targets. To test this hypothesis while controlling for genetic background,
we performed an epigenome-wide analysis of DNA methylation in genomic DNA from whole
blood in three pairs of female monozygotic (MZ) twins of European ancestry, discordant for SLE.
Results were replicated on the same array in four cell types from a set of four Danish female MZ
twin pairs discordant for SLE. Genes implicated by the epigenetic analyses were then evaluated
in 10 independent SLE gene expression datasets from the Gene Expression Omnibus (GEO). There
were 59 differentially methylated loci between unaffected and affected MZ twins in whole blood,
including 11 novel loci. All but two of these loci were hypomethylated in the SLE twins relative to
the unaffected twins. The genes harboring these hypomethylated loci exhibited increased expression
in multiple independent datasets of SLE patients. This pattern was largely consistent regardless of
disease activity, cell type, or renal tissue type. The genes proximal to CpGs exhibiting differential
methylation (DM) in the SLE-discordant MZ twins and exhibiting differential expression (DE) in
independent SLE GEO cohorts (DM-DE genes) clustered into two pathways: the nucleic acid-sensing
pathway and the type I interferon pathway. The DM-DE genes were also informatically queried
for potential gene–drug interactions, yielding a list of 41 drugs including a known SLE therapy.
The DM-DE genes delineate two important biologic pathways that are not only reflective of the
heterogeneity of SLE but may also correlate with distinct IFN responses that depend on the source,
type, and location of nucleic acid molecules and the activated receptors in individual patients. Cell-
and tissue-specific analyses will be critical to the understanding of genetic factors dysregulating the
nucleic acid-sensing and IFN pathways and whether these factors could be appropriate targets for
therapeutic intervention.
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1. Introduction
Systemic lupus erythematosus (SLE) is a chronic and severe systemic autoimmune
disease characterized by the over-production of autoantibodies and heterogeneous clinical
manifestations. With more than 100 risk loci identified, a genetic etiology for SLE is
unequivocal [1–8]. In fact, the cumulative effect of these risk loci is substantial; the odds
ratio (OR) for SLE in individuals of European ancestry is 30 when comparing individuals
with the highest 10% of risk allele genetic load (i.e., polygenetic risk score—the weighted
count of the number of risk alleles) to individuals in the lowest 10% of genetic load [6].
Despite the strong genetic contribution to risk, the concordance rate between monozygotic
(MZ) twins ranges between 24–35%, suggesting that much of the risk remains unexplained
and highlighting the potential importance of epigenetic and environmental factors in SLE
susceptibility [9].
There is compelling evidence that epigenetic mechanisms, such as 5’ Cytosine methy-
lation, are involved in the pathogenesis of SLE. For example, promoter demethylation at
multiple genes in T cells treated with DNA demethylating agents are sufficient to cause
lupus in animal models [10]. In recent years, several studies have investigated DNA methy-
lation in SLE patients on a genome-wide scale. The earliest of these genome-wide studies
interrogated 27,578 CpG sites in 12 SLE patients and 12 healthy controls using the Illumina
Infinium HumanMethylation27 Beadchip, and identified 336 differentially methylated
genes, the majority of which were hypomethylated in the cases relative to the controls [11].
Subsequent studies have examined genome-wide methylation in larger samples of SLE
patients using the HumanMethylation450 Beadchip (>485,000 CpG sites) in a number of cell
types, including naïve CD4+ T cells [12–16], memory and regulatory T cells [17], CD19+ B
cells [17], CD14+ monocytes [14,17], granulocytes [14], neutrophils [18], and whole blood or
peripheral blood mononuclear cells (PBMC) [19–25]. Differential methylation has not only
been observed when comparing SLE patients to healthy controls, but similar patterns have
been identified in SLE patients with nephritis [12,19,22], skin involvement [13], specific
antibodies [20], and pediatric SLE [26]. The primary and consistent finding across all these
studies has been hypomethylation of interferon-regulated genes across various cell types
in cases, regardless of SLE disease activity [27].
The analysis of phenotypically discordant MZ twins represents the ideal design by
which to assess the role of epigenetic variation in disease etiology and trait heritability
while controlling for genetic background [28] and has revealed the existence of differentially
methylated regions associated with several autoimmune diseases, including SLE [29], type
1 diabetes [30], psoriasis [31], and ulcerative colitis [32]. To date, the only previously
published twin methylation study in SLE that exclusively used MZ twins quantified DNA
methylation in white blood cells from 15 discordant MZ twin pairs at 1505 CpG sites
in 807 genes using the Illumina GoldenGate Methylation Cancer Panel I [29]. Here, we
performed a genome-wide analysis of DNA methylation in a discovery cohort of MZ twins
discordant for SLE. The discovery cohort consisted of three twin pairs of European descent,
and methylation was measured in whole blood using Illumina’s HumanMethylation450
Beadchip. The two strongest associated signals were validated using pyrosequencing.
Findings from the discovery cohort were replicated in an independent set of MZ twins
from Denmark. We then evaluated gene expression data from multiple cell types and
kidney biopsies from 10 independent SLE cohorts to identify genes proximal to CpGs
exhibiting differential methylation (DM) in the SLE-discordant MZ twins and exhibiting
differential expression (DE) in independent SLE GEO cohorts (DM-DE genes) for pathway
analyses. Together, the methylation, gene expression, and pathway analyses uncovered
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two separable yet complimentary molecular pathways of lupus pathogenesis, shedding
light on potential drug repositioning opportunities and novel therapeutic targets for SLE.
2. Materials and Methods
2.1. Discovery Cohort
Genomic DNA was extracted from peripheral blood of three female MZ twin pairs of
European ancestry discordant for SLE enrolled in the Lupus Family Registry and Repository
(LFRR) [33]. All cases met ACR classification criteria for SLE [34].
2.2. Replication Cohort
An SLE study of 15 twin pairs from Denmark, assayed on the HumanMethylation450
Beadchip, in monocytes, CD4+ T cells, CD19+ B cells, and granulocytes, was published in
2018 by Ulff-Moller et al. [14]. These data were downloaded from the Gene Expression Om-
nibus (GEO, accession no. GSE110607), and all available female MZ twin pairs discordant
for SLE were retained for analysis (4 twin pairs). The publication states that of these four
female MZ twin pairs discordant for SLE, two of the non-SLE twins had other autoimmune
diseases, including Sjogren’s syndrome, systemic sclerosis, autoimmune thyroiditis, and
primary biliary cirrhosis. However, this clinical information was not available in GEO.
2.3. Genome-Wide DNA Methylation Assay and Array Validation in LFRR Twins
Genomic DNA (1µg) from each individual was treated with sodium bisulfite using
the EZ 96-DNA methylation kit (Zymo Research, Irvine, CA, USA), following the man-
ufacturer’s standard protocol. Genome-wide DNA methylation was assessed using the
Illumina Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, CA, USA),
which interrogates over 485,500 CpG sites that cover 99% of RefSeq genes (including the
promoter, 5’UTR, first exon, gene body, and 3’UTR), as well as 96% of CpG islands and
island shores. Arrays were processed using the manufacturer’s standard protocol, with
both members of each twin pair being hybridized to the same row on the microarray to
minimize batch effects. GenomeStudio software (Illumina, Inc.) was used to perform
initial quality control and to calculate the relative methylation level of each interrogated
cytosine, which is reported as a β-value given by the ratio of the normalized signal from
the methylated probe to the sum of the normalized signals of the methylated and unmethy-
lated probes. This β-value for each CpG site ranges from 0 (unmethylated) to 1 (fully
methylated). CpG loci with a stringent detection p-value > 1.0 × 10−5 in any of the samples
were excluded (n = 2118 probes) to control for poor-quality assays. Validation of the array
data in the LFRR twins was performed by pyrosequencing two of the most significant
CpGs probes: cg13304609 (in IFI44L) and cg23570810 (in IFITM1). The correlations between
the methylation proportions from the array and pyrosequencing for these two probes were
r2 = 0.98 and r2 = 0.99, respectively.
2.4. Collection of Gene Expression Experiments from SLE Patient Datasets
Raw data were downloaded from 10 publicly available gene expression datasets (Sup-
plemental Table S1). Only datasets from female lupus patients were analyzed. Active SLE
was defined as a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) > 6 [35].
This has become the standard threshold for disease activity in recent clinical trials of SLE.
2.5. Data Analysis
To identify differentially methylated genes between unaffected and SLE-affected
twins, a paired t-test on the probe-specific β-values was computed separately for the
discovery and replication twin datasets. For the discovery set, CpG sites meeting (1) the
Benjamini–Hochberg False Discovery Rate (FDR) [36] threshold PFDR < 0.05 (equivalent to
p < 1.06 × 10−7) and (2) a mean DNA methylation difference of (∆β) > |0.085| were con-
sidered statistically significant; the mean methylation difference threshold was obtained by
maximizing the area under the receiver operator characteristic curve (AUC) as a function of
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the β-value (described below). The genes related to the differentially methylated CpG sites
(as annotated by Illumina for the HumanMethylation450) were queried in the Interferome
online database to identify interferon-regulated genes [37]. In addition, significant CpG
sites were investigated for evidence of association between DNA methylation pattern and
gene expression (mQTL) using the iMETHYL genome browser [38]. These results are based
on 100 healthy subjects with RNA-seq data and DNA methylation data in CD4T cells,
monocytes, and PBMC.
Statistical analysis of the expression data was completed using the following R
packages available from Bioconductor: GEOquery, affy, affycoretools, simpleaffy, gcrma,
LIMMA, and GSVA. Non-normalized arrays were first inspected for visual artifacts and
poor RNA hybridization using Affymetrix QC plots. Principal component (PC) plots were
generated for all cell types in each experiment to identify outliers. After removing outliers,
the datasets were normalized using the gcrma package (available in Bioconductor [39],
www.bioconductor.org) resulting in log2 intensity values for the R expression set objects
(denoted E-sets); an E-set combines several information types in a single structured object:
an expression value matrix, phenotypic metadata corresponding to individual samples
(phenoData), annotation data describing each feature (probeset) of a microarray platform
(featureData), as well as other separate metadata matrices describing the experimental
protocol and array platform design. To increase the probability of identifying differen-
tially expressed genes (DE genes), the analyses were completed using normalized datasets
prepared using both the native Affymetrix chip definition file (CDF), as well as custom
BrainArray Entrez CDFs. Illumina CDFs were used for GSE49454.
The CDF-annotated E-sets were filtered to remove probes with very low intensity
values by computing the mean log2 values for each probe across all samples and removing
those in the lower half of the range of mean values from the expression set (E-set). Probes
missing gene annotation data were also discarded. GCRMA normalized expression values
were variance-corrected using local empirical Bayesian shrinkage before calculation of
differential expression using the ebayes function in the Bioconductor limma package [40].
The resulting p-values were adjusted for multiple hypothesis testing using Benjamini–
Hochberg False Discovery Rate (FDR) [36]. Significant Affymetrix and BrainArray probes
within each study were merged and filtered to retain DE probes with a PFDR < 0.2. This
list was filtered to retain only the most significant probe per gene.
To identify DM-DE genes, we used a logistic regression model (expression fold change
as a binary outcome > 0 versus < 0) to determine cell-type specific thresholds for the
difference in the β-value that maximized the area under the ROC curve (AUC) predicting
increased differential expression (Figure 1A, Supplemental Figure S1). These thresholds
were determined by calculating the area under the receiver operating characteristic curve
(AUC) across points at regular intervals between 0 and −0.15 and selecting the values
that maximized the AUC. Primary inferences are based on thresholds, which included a
logFC in expression > 0 and a mean difference in β < −0.085, −0.055, −0.08, and −0.055
in whole blood, monocytes, B cells, and T cells, respectively. Figure 1A displays these
thresholds as vertical bars. For clarity, genes with differential methylation p-values greater
than 0.0001 and a mean DNA methylation difference of (∆β) > |0.025| have been removed
from Figure 1A.
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Figure 1. Hypomethylated genes showing differential expression in independent SLE cohorts.
(A) Specific thresholds for the difference in the β-value (from the discordant twin methylation
experime in whole blood) that maximize the area under the ROC curve predicting increased
differential expression in the independent SLE whole blood experiments (GSE39088, GSE49454),
monocytes (GSE38351), B-cells (GSE10325, GSE4588), and T cells (GSE10325, GSE51997) are shown
as vertical bars. Genes with differential methylation p-values greater than 0.0001 and a mean DNA
methylation difference of (∆β) > |0.025| have been removed from the plots. (B) Heatmap of 43 genes
hypomethylated in the discordant twin data (∆β < −0.085) and differentially expressed between
controls and active (SLEDAI ≥ 6) or inactive (SLEDAI < 6) lupus patients from two whole blood
experiments, monocytes, B cells, and T cells. Hierarchical clustering was performed across rows with
Euclidean distance metric and complete linkage. Blue/red gradient represents the log fold change
values in lupus patients compared to controls.
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The DM-DE genes were analyzed in a pathway analysis using the MCODE [41]
clustering algorithm and STRING networking scores [42].
Protein–drug interaction networks were generated for each DM-DE gene individually
via STITCH [43], Ingenuity Pathway Analysis (IPA) (Qiagen Bioinformatics: ingenuity.com),
and the Drug–Gene Interaction database [44]. Drugs were denoted as (1) known utility
in lupus therapy, (2) FDA-approved compound, (3) currently involved in a clinical trial
(not necessarily SLE), and (4) generally regarded as safe (GRAS) compounds. Using a
hypothesis-driven ranking of the therapeutic potential for SLE applications of specific
drugs or compounds, the combined lupus treatment scoring (CoLTS) scores (range −16 to
+11) were calculated [45].
3. Results
3.1. Characteristics of the MZ Twins
The LFRR MZ twins were all females of European ancestry, and the SLE-diagnosed
twins exhibited a range of SLE clinical conditions (Supplemental Table S2). The Danish
MZ twins were also all females of European ancestry. Clinical characteristics such as
number of ACR criteria, SLEDAI score, autoantibodies, and medications are described in
Ulff-Moller et. al., but were not available in GEO [14].
3.2. Identification of Differentially Methylated Regions in Twins Discordant for SLE
Of the 485,577 CpG sites passing quality control metrics, 59 sites in 33 genes met both a
PFDR < 0.05 (equivalent to a non-FDR p < 1.06 × 10−7) and a mean DNA methylation differ-
ence of (∆β) > |0.085| (Table 1). Only two of these significant CpG sites showed increased
methylation in the affected twins (hypermethylation), while the remaining 57 exhibited
lower methylation (hypomethylation). Of the 33 genes represented in Table 1, 22 are
regulated at some level by type I interferons (as defined by Interferome [37]). Eleven
genes are novel to our study and have not been previously reported as SLE-related in
a genome-wide methylation study, five of which are unrelated to the typical interferon
signature (LY6G5C, CXCR1, ATOH8, CACNA1D, MECOM). Lymphocyte antigen 6 complex,
locus G5C (LY6G5C), is located within the major histocompatibility complex class III region
and codes for a protein associated with the cell membrane by a glycosylphosphatidylinosi-
tol linkage and involved in signal transduction [46]. Chemokine (C-X-C motif) receptor
1 (CXCR1) encodes for a protein that is a receptor for interleukin 8. Genetic and expression
variation in CXCR1 have been correlated with infections (e.g., active tuberculosis, hepatitis
B, Candida albicans) and modestly with SLE [6,47–50]. Atonal bHLH transcription factor
8 (ATOH8), calcium voltage-gated channel subunit alpha1 D (CACNA1D), and MDS1, and
EVI1 complex locus (MECOM) do not have known links to autoimmune disease or infec-
tions. Given the gender bias in SLE, it is interesting to note that none of the differentially
methylated probes meeting our significance criteria were located on the X chromosome.
We next examined the 59 differentially methylated CpGs from the discovery cohort
(Table 1) in the Danish twin replication cohort. Even with the probable dampening effect
generated by two of the Danish non-SLE twins having other autoimmune diseases, we
observed very high concordance in the direction of the ∆β values. Specifically, 55 (93%),
54 (92%), 52 (88%), and 54 (92%) of the 59 differentially methylated CpG sites in the
LFRR twins were concordant in the Danish twins’ monocytes, CD4+ T cells, CD19+ B
cells, and granulocytes, respectively. Furthermore, 35, 26, 32, and 33 of the 59 CpG sites
were statistically significant (p-value < 0.05) and directionally concordant in the monocyte,
CD4+ T cell, CD19+ B cell, and granulocyte expression datasets, respectively; only one
of these was statistically significant in the opposite direction (p-value < 0.05; Additional
File 1). Thus, the Danish twin data strongly corroborated the global pattern of methylation
observed in the LFRR twin data.
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Table 1. Differentially methylated probes from three monozygotic twin pairs discordant for SLE.





CpG ††Pair1 Pair2 Pair3 Mean
cg13304609 1 79085162 IFI44L −0.24 −0.27 −0.37 −0.29 1.58 × 10−14 IRG
cg06872964 1 79085250 IFI44L −0.26 −0.21 −0.24 1.05 × 10−71 IRG
cg03607951 1 79085586 IFI44L −0.27 −0.3 −0.21 −0.26 7.23 × 10−22 IRG
cg17515347 1 159047163 AIM2 −0.09 −0.11 −0.07 −0.09 3.01 × 10−12 IRG
cg08272268 1 200380059 ZNF281 −0.08 −0.07 −0.11 −0.09 4.33 × 10−15 S_Shore
cg01028142 2 7004578 CMPK2 −0.22 −0.36 −0.43 −0.33 7.98 × 10−8 IRG N_Shore
cg10959651 2 7018020 RSAD2 −0.13 −0.1 −0.16 −0.13 3.14 × 10−14 IRG
cg10549986 2 7018153 RSAD2 −0.08 −0.09 −0.1 −0.09 1.95 × 10−91 IRG
cg14126601 2 37384708 EIF2AK2 −0.08 −0.1 −0.12 −0.1 5.55 × 10−16 IRG S_Shore
cg26337070 2 85999873 ATOH8 −0.06 −0.12 −0.11 −0.1 7.55 × 10−9
cg04781494 2 202047246 CASP10 −0.07 −0.13 −0.08 −0.09 8.39 × 10−8 IRG
cg15768138 2 219030752 CXCR1 −0.09 −0.12 −0.11 −0.11 7.38 × 10−27
cg13411554 3 53700276 CACNA1D −0.06 −0.12 −0.09 −0.09 8.66 × 10−8
cg22930808 3 122281881 PARP9-DTX3L −0.36 −0.34 −0.4 −0.37 6.74 × 10
−126 IRG N_Shore
cg08122652 3 122281939 PARP9-DTX3L −0.34 −0.31 −0.51 −0.38 1.11 × 10
−9 IRG N_Shore
cg00959259 3 122281975 PARP9-DTX3L −0.37 −0.3 −0.34 −0.34 1.32 × 10
−56 IRG N_Shore
cg06981309 3 146260954 PLSCR1 −0.24 −0.28 −0.21 −0.24 6.41 × 10−31 IRG N_Shore
cg02556393 3 168866705 MECOM −0.08 −0.09 −0.1 −0.09 3.14 × 10−95 N_Shore
cg07809027 4 15007205 CPEB2 −0.07 −0.1 −0.12 −0.1 2.08 × 10−14 S_Shore
cg02215171 4 89379156 HERC5 −0.08 −0.09 −0.11 −0.09 4.48 × 10−18 IRG S_Shore
cg17786255 4 108814389 SGMS2 −0.07 −0.09 −0.11 −0.09 2.01 × 10−16 IRG
cg21873524 4 190942744 −0.1 −0.1 −0.12 −0.11 1.03 × 10−55 Island
cg24740632 5 134486678 −0.11 −0.12 −0.14 −0.12 2.26 × 10−60
cg06012695 6 28770593 −0.1 −0.13 −0.11 3.59 × 10−16
cg25138053 6 31368016 −0.11 −0.09 −0.07 −0.09 3.67 × 10−15 S_Shore
cg22708150 6 31649619 LY6G5C −0.12 −0.14 −0.17 −0.14 1.05 × 10−19 N_Shore
cg07292773 6 156718177 0.07 0.1 0.11 0.1 2.22 × 10−17 Island
cg12013713 7 139760671 PARP12 −0.12 −0.14 −0.09 −0.12 1.44 × 10−16 IRG N_Shore
cg20190772 8 48572496 KIAA0146 −0.08 −0.07 −0.13 −0.09 1.40 × 10−8
cg14864167 8 66751182 PDE7A −0.25 −0.35 −0.45 −0.35 1.21 × 10−9 N_Shelf
cg06102678 8 81491328 −0.08 −0.12 −0.07 −0.09 1.00 × 10−8 Island
cg12110437 8 144098888 LY6E −0.16 −0.17 −0.27 −0.2 3.14 × 10−9 IRG N_Shore
cg17555806 10 74448117 −0.08 −0.12 −0.07 −0.09 1.51 × 10−8 N_Shelf
cg02314339 10 91020653 −0.08 −0.14 −0.11 −0.11 1.72 × 10−8
cg06188083 10 91093005 IFIT3 −0.29 −0.16 −0.31 −0.25 6.18 × 10−8 IRG
cg05552874 10 91153143 IFIT1 −0.2 −0.28 −0.3 −0.26 6.01 × 10−16 IRG
cg14910175 10 131840954 −0.07 −0.11 −0.08 −0.09 1.56 × 10−11 N_Shelf
cg10552523 11 313478 IFITM1 −0.14 −0.12 −0.14 −0.13 5.90 × 10−115 IRG N_Shelf
cg20566897 11 313527 IFITM1 −0.11 −0.11 −0.09 −0.1 7.00 × 10−62 IRG N_Shelf
cg23570810 11 315102 IFITM1 −0.24 −0.25 −0.34 −0.27 1.43 × 10−18 IRG N_Shore
cg03038262 11 315262 IFITM1 −0.24 −0.22 −0.29 −0.25 4.41 × 10−40 IRG N_Shore
cg20045320 11 319555 −0.19 −0.13 −0.2 −0.18 4.85 × 10−17 S_Shore
cg17990365 11 319718 IFITM3 −0.16 −0.15 −0.15 −0.16 8.78 × 10−295 IRG S_Shore
cg08926253 11 614761 IRF7 −0.15 −0.14 −0.23 −0.17 2.01 × 10−9 IRG Island
cg12461141 11 5710654 TRIM22 −0.1 −0.08 −0.12 −0.1 6.35 × 10−25 IRG
cg23571857 17 6658898 XAF1 −0.07 −0.13 −0.11 −0.1 1.46 × 10−8 IRG
cg04927537 17 76976091 LGALS3BP −0.14 −0.11 −0.2 −0.15 2.77 × 10−10 IRG
cg25178683 17 76976267 LGALS3BP −0.15 −0.11 −0.21 −0.16 2.01 × 10−8 IRG
cg16503797 18 19476805 −0.08 −0.12 −0.08 −0.09 5.39 × 10−12 N_Shore
cg15871086 18 56526595 −0.07 −0.11 −0.08 −0.09 2.08 × 10−11 N_Shelf
cg23352030 20 62198469 PRIC285 0.13 0.19 0.11 0.14 2.36 × 10−11 Island
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Table 1. Cont.





CpG ††Pair1 Pair2 Pair3 Mean
cg16785077 21 42791867 MX1 −0.11 −0.09 −0.12 −0.11 8.45 × 10−27 IRG N_Shore
cg22862003 21 42797588 MX1 −0.31 −0.25 −0.35 −0.31 1.62 × 10−25 IRG N_Shore
cg26312951 21 42797847 MX1 −0.26 −0.17 −0.2 −0.21 6.28 × 10−15 IRG N_Shore
cg21549285 21 42799141 MX1 −0.5 −0.35 −0.57 −0.47 6.59 × 10−13 IRG S_Shore
cg05543864 22 24979755 GGT1 −0.08 −0.08 −0.1 −0.09 1.44 × 10−45
cg20098015 22 50971140 ODF3B −0.19 −0.22 −0.21 −0.21 9.88 × 10−83 IRG S_Shore
cg05523603 22 50973101 −0.17 −0.23 −0.27 −0.22 5.51 × 10−14 S_Shelf
cg02247863 22 50983415 −0.07 −0.1 −0.11 −0.09 2.51 × 10−13 N_Shore
* CpGs meeting the PFDR < 0.05 threshold (equivalent to p < 1.06 × 10−7) and having |∆β| > 0.085. † Positions are from Build 37. ‡ IRG as
defined by Interferome [37]. †† Island: CpG sites > 200 bp, with GC content > 55% and observed to expected ratio > 0.6. N_shore: 0–2
kb upstream from island; S-shore 0–2 kb downstream from island; N_shelf 2–4 kb upstream from island; S_shelf 2–4 kb downstream
from island.
We also sought to determine if the dominating presence of the interferon signature
might have masked more modest signals from other individual (non-IFN) loci. After
regressing out the mean β-value (methylation value) for the most significant CpG site in
each interferon-regulated gene in Table 1 (as defined by Interferome [37]), no additional
CpG sites across the genome met an FDR threshold of significance (PFDR > 0.05).
We considered the genomic context of the CpG sites showing aberrant methylation in
the LFRR MZ twins. Here, a CpG island was defined as a cluster of CpG sites of greater
than 200 bp, with GC content >55%, and the observed-to-expected (under mathematical in-
dependence of the Gs and Cs) ratio >0.6 [51]. Interestingly, out of 59 CpG sites differentially
methylated, the majority (54%, n = 32) were located in a CpG shore (0–2 kb from island) or
shelf (2–4 kb from island), whereas only 8% (n = 5) were located in a CpG island (Table 1).
This is in contrast to the composition of the 450k chip in which about one third of the CpG
sites reside in islands (Supplemental Figure S2). Notably, the only two hypermethylated
CpG sites (relative to the unaffected twin) meeting our significance thresholds reside in
CpG islands.
3.3. Hypomethylated Genes Are Overexpressed in Independent Cohorts
Methylation at CpG sites influences gene expression. Thus, linking differential methy-
lation to changes in gene expression by showing that the same genes were associated with
SLE in both types of experiments (even in independent samples) would provide further evi-
dence of the importance of these genes and could identify potential actionable mechanisms.
Genes harboring a CpG site with ∆β < −0.085 and p < 0.01 (for differential methyla-
tion) were tested for differential expression in whole blood from two independent cohorts,
each comparing SLE patients to healthy controls (GSE39088 and GSE49454) (Table 2).
Relative to controls, overexpression was observed in both active and inactive SLE pa-
tients within almost all of these genes, and the level of expression was highly correlated
within the gene expression experiments (experiment 1, r = 0.95; experiment 2, r = 0.99).
IFI44L, RADS2, and IFIT1 showed the highest fold changes and comparable increases
in expression in active and inactive SLE patients; IFI44L is noteworthy as it has been
reported to be predictive of SLE status relative to healthy controls and other autoimmune
diseases [52]. Cohorts with expression data derived from monocytes (GSE38351), CD19+,
and CD20+ B cells (GSE10325, GSE4588), and CD4+ T cells (GSE10325, GSE51997) reflected
a consistent pattern of increased expression in genes meeting the mean (methylation)
∆β threshold of −0.085 (Figure 1B). Upon extending ∆β to <−0.055, the statistically ap-
propriate threshold for detecting differential expression in monocytes and T cells in our
dataset (see Methods), an additional 54 hypomethylated genes were evaluated in the gene
expression datasets (Supplemental Table S3). Overall, the pattern of differential expression
of hypomethylated genes was very similar across the cell subtypes examined (Figure 1B,
Supplemental Table S3). Thus, the differential expression results in independent cohorts in
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multiple cell types provide a multi-omic, independent pseudo-replication, and translational
interpretation of the methylation results (Table 2).
Hierarchical clustering (Euclidean distance, complete linkage) of the DM-DE genes
using the log fold change (LFC) identified a cluster of nine genes with markedly higher
LFC (Figure 1B). This cluster shows a consistent pattern across whole blood, monocytes,
B cells, and T cells, as well as in both active and inactive SLE disease. In fact, the LFC
remained largely consistent between active and inactive disease across all DM-DE genes.
Exceptions to this pattern include FK506 binding protein 5 (FKBP5), parvin beta (PARVB),
and strawberry notch homolog 2 (SBNO2) in whole blood, where there is upregulation
in active patients and non-significant change in inactive patients. This pattern was not
replicated in any of the individual cell types.
Table 2. Differential expression of hypomethylated genes in whole blood from two independent SLE cohorts.
Active SLE § Inactive SLE §











cg16526047 1 949893 ISG15 −0.11 1.28 × 10−4 IRG 3.1 2.77 2.74 2.59
cg05696877 1 79088769 IFI44L −0.3 6.60 × 10−6 IRG 3.98 3.8 3.64 3.4
cg01079652 1 79118191 IFI44 −0.34 5.34 × 10−4 IRG 3.54 2.53 3.7 2.33
cg17515347 1 159047163 AIM2 −0.09 3.01 × 10−12 IRG 1.39 0.86 1.08 0.49
cg01028142 2 7004578 CMPK2 −0.33 7.98 × 10−8 IRG 2.76 1.5 2.43 1.51
cg10959651 2 7018020 RSAD2 −0.13 3.14 × 10−14 IRG 4.04 3.32 3.76 3.04
cg14126601 2 37384708 EIF2AK2 −0.1 5.55 × 10−16 IRG 1.47 2.02 1.08 1.68
cg15768138 2 219030752 CXCR1 −0.11 7.38 × 10−27 0.43 0.96 0.38 0.66
cg08122652 3 122281939 PARP9-DTX3L −0.38 1.11 × 10
−9 IRG 1.36 1.56 1.07 1.55
cg06981309 3 146260954 PLSCR1 −0.24 6.41 × 10−31 IRG 1.77 1.25 1.38 1.07
cg02694620 3 172109284 FNDC3B −0.11 3.80 × 10−3 0.57 0.82 0.41 0.52
cg15065340 3 195632915 TNK2 −0.16 4.04 × 10−3 0.22 0.31 0.2 0.25
cg07809027 4 15007205 CPEB2 −0.1 2.08 × 10−14 0.66 0.52 0.42 0.45
cg02215171 4 89379156 HERC5 −0.09 4.48 × 10−18 IRG 2.62 2.48 2.14 2.36
cg05883128 4 169239131 DDX60 −0.25 2.13 × 10−5 IRG 1.24 1.38 1.06 1.46
cg08099136 6 32811251 PSMB8 −0.11 1.43 × 10−4 IRG −0.39 −0.13 NS NS
cg00052684 6 35694245 FKBP5 −0.16 1.65 × 10−3 1.11 0.71 NS NS
cg05994974 7 139761087 PARP12 −0.15 6.89 × 10−5 IRG 1.52 1.57 1.14 1.25
cg14864167 8 66751182 PDE7A −0.35 1.21 × 10−9 −1.24 −0.41 −0.82 −0.23
cg12110437 8 144098888 LY6E −0.2 3.14 × 10−9 IRG 2.66 1.92 2.43 1.7
cg03848588 9 32525008 DDX58 −0.1 4.34 × 10−4 IRG 1.48 1.3 1.32 1.07
cg06188083 10 91093005 IFIT3 −0.25 6.18 × 10−8 IRG 2.25 3.15 2.3 2.87
cg05552874 10 91153143 IFIT1 −0.26 6.01 × 10−16 IRG 3.39 2.94 3.42 2.81
cg23570810 11 315102 IFITM1 −0.27 1.43 × 10−18 IRG 1 1.03 1.03 0.81
cg17990365 11 319718 IFITM3 −0.16 8.78 × 10−295 IRG 0.92 2.23 0.71 2.13
cg08926253 11 614761 IRF7 −0.17 2.01 × 10−9 IRG 1.84 1.79 1.4 1.37
cg08577913 11 4415193 TRIM21 −0.1 1.74 × 10−3 IRG 0.56 0.93 0.28 0.75
cg12461141 11 5710654 TRIM22 −0.1 6.35 × 10−25 IRG 1.14 1 0.99 1.05
cg26811705 11 118781408 BCL9L −0.09 1.64 × 10−3 −0.6 −0.35 −0.41 −0.32
cg19347790 12 81332050 LIN7A −0.09 1.87 × 10−4 0.93 0.99 1.24 0.61
cg25800166 12 113375896 OAS3 −0.13 5.36 × 10−5 IRG 2.52 2.69 0.73 2.35
cg19371652 12 113415883 OAS2 −0.11 2.24 × 10−5 IRG 1.48 1.56 1.64 1.53
cg03753191 13 43566902 EPSTI1 −0.1 9.23 × 10−5 IRG 2.65 2.26 2.71 2.02
cg00246969 13 99159656 STK24 −0.11 6.26 × 10−6 0.81 0.32 0.66 0.36
cg07839457 16 57023022 NLRC5 −0.23 6.10 × 10−6 IRG 0.7 0.23 0.53 0.27
cg23571857 17 6658898 XAF1 −0.1 1.46 × 10−8 IRG 2.85 1.96 2.35 1.68
cg23378941 17 64361956 PRKCA −0.11 6.89 × 10−5 IRG −1.11 −0.3 NS NS
cg25178683 17 76976267 LGALS3BP −0.16 2.0 × 10−8 IRG 1.16 1.21 0.72 1.05
cg07573872 19 1126342 SBNO2 −0.15 2.77 × 10−3 IRG 0.38 0.58 NS NS
cg07839313 19 17514600 BST2 −0.12 3.48 × 10−3 IRG 1.24 0.49 1.17 0.41
cg21549285 21 42799141 MX1 −0.47 6.59 × 10−13 IRG 2.12 2 1.86 1.79
cg19460508 22 44422195 PARVB −0.1 1.64 × 10−3 0.54 0.39 NS NS
cg20098015 22 50971140 ODF3B −0.21 9.88 × 10−83 IRG 1.61 0.61 1.36 0.47
Differential gene expression values come from GSE39088 (Expt 1) and GSE49454 (Expt 2) in whole blood of lupus patients compared with
controls. * CpGs with p < 0.01 and |∆β| > 0.085. † Positions are from Build 37. ‡ As defined by Interferome [37]. § Active disease is defined
as ≥6 on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [35].
Genes 2021, 12, 1898 10 of 20
Although only one of the three affected MZ twins in the discovery cohort had renal
involvement, almost all of the genes mapping to differentially methylated CpG sites showed
overexpression in both the kidney glomerulus and tubulointerstitium from independent
lupus nephritis patients (Table 3). In the glomerulus, 28 genes were overexpressed, 2 were
under expressed, and 14 were not significantly differentially expressed in lupus nephritis
samples compared to healthy controls. In the tubulointerstitium, 27 were overexpressed,
5 under expressed, and 12 not significantly differentially expressed. IFI44L, MX1, and IFI44
showed the highest levels of overexpression across the two tissues. The fold change was
correlated between the two tissues (r = 0.66, p < 0.0001).
Significant DNA methylation sites were further investigated for evidence of associa-
tion between DNA methylation at a specific CpG site and gene expression (eQTM) using
the iMETHYL genome browser with data on 100 healthy Japanese subjects with RNA-seq
data and DNA methylation data in CD4T cells, monocytes, and PBMC [38] (Supplemental
Table S4). Most of the CpGs from Table 1 that are identified in iMETHYL are eQTMs for
the gene in which they reside. In contrast, some are eQTMs for additional genes of interest.
For example, cg17515347 is in physical proximity to AIM1, which has an important role
in T cell regulation in autoimmune diseases. However, this CpG site is also an eQTM for
five other genes in CD4+ T cells (TAGLN2, SLAMF8, DUSP23, PHYIN1 FCRL6), several of
which have established autoimmune disease connections. Transgelin-2 may help regulate
activation and migration of B cells in lymph node follicles, exhibits increased expression in
B cells from lymph nodes in SLE patients, and appears important in host defense [53,54].
SLAM family member 8 (SLAMF8) is a member of the SLAM family of genes of which
several members have been associated with multiple autoimmune diseases [55]. FcR-like 6
(FCRL6), a receptor that binds to major histocompatibility complex (MHC) class II HLA-
DR, is expressed in B cells and has a tyrosine-based immunoregulatory function [56,57].
Dual-specificity protein phosphate 23 (DUSP23) expression is reportedly higher in CD4+ T
cells from SLE patients compared to healthy controls [58]. Thus, DNA methylation in these
regions, and potentially others, may have a complex and multifaceted impact on autoim-
munity. Annotation of cg20098015 on chromosome 22 is linked to Outer Dense Fiber of
Sperm Tails 3 (ODF3B). However, this CpG is an eQTM for SCO2 homolog, mitochondrial
and SCO cytochrome oxidase deficient homolog 2 (SCO2), and thymidine phosphorylase
(TYMP), both involved in mitochondrial functions.
3.4. Pathway Analysis of DM-DE Genes
Pathway, clustering, and networking analyses were completed to elucidate patterns
among the DM-DE genes. Ingenuity Pathway Analysis (IPA) identified two primary
canonical pathways: (1) interferon signaling and (2) pattern recognition receptor (PRR)
(Figure 2A). The overlap p-value, which tests for independence between known targets
of each transcription regulator in a pathway and the list of genes provided, shows very
strong association for these two pathways. Other significant pathways of note include
the activation of interferon regulatory factors (IRFs) by pattern recognition receptors,
retinoic acid-inducible gene I protein (RIG-I)-like receptors in innate immunity, and NF-κB
activation by viruses. Figure 2B illustrates the IFN signaling pathway determined by
IPA. Notably, in this pathway all of the DM-DE genes are downstream, and none were
identified as upstream signaling molecules. IPA also identified 39 upstream regulators
(|Z-score| ≥ 2) of the DM-DE genes that showed differential expression between SLE
cases and controls in whole blood (Figure 2C).
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 Figure 2. Pathway analyses of hypomethylated genes showing differential expression in independent
SLE cohorts. (A) List and statistical significance of the overlap of the IPA canonical pathways com-
prised of hypomethylated genes showing differential expression in whole blood of independent SLE
patients. (B) IPA canonical IFN signaling of hypomethylated genes showing differential expression
(increased expression in SLE cases in red) in whole blood of independent SLE patients. (C) Activation
Z-scores of genes predicted as upstream regulators of genes hypomethylated in the discordant twin
data (∆β < −0.085) and differentially expressed in whole blood between independent SLE cases
and controls. A positive (negative) Z-score indicates that a regulator has significantly more (fewer)
activated predictions than inhibited predictions.
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Table 3. Differential expression of hypomethylated genes in kidney biopsies from independent SLE patients with
lupus nephritis.







cg16526047 1 949893 ISG15 ‖ −0.11 1.28 × 10−4 IRG 3.32 4.7
cg05696877 1 79088769 IFI44L ∆ −0.3 6.60 × 10−6 IRG 5.14 5.94
cg01079652 1 79118191 IFI44 ‖ −0.34 5.34 × 10−4 IRG 3.94 4.76
cg17515347 1 159047163 AIM2 −0.09 3.01 × 10−12 IRG 0.58 NS
cg01028142 2 7004578 CMPK2 ∆ −0.33 7.98 × 10−8 IRG NS NS
cg10959651 2 7018020 RSAD2 −0.13 3.14 × 10−14 IRG 4.31 3.36
cg14126601 2 37384708 EIF2AK2 ∆ −0.1 5.55 × 10−16 IRG 1.54 1.72
cg15768138 2 219030752 CXCR1 −0.11 7.38 × 10−27 0.68 −0.17
cg08122652 3 122281939 PARP9-DTX3L ∆ −0.38 1.11 × 10−9 IRG NS NS
cg06981309 3 146260954 PLSCR1 ∆ −0.24 6.41 × 10−31 IRG 1.92 2.07
cg02694620 3 172109284 FNDC3B −0.11 3.80 × 10−3 NS 0.47
cg15065340 3 195632915 TNK2 ‖ −0.16 4.04 × 10−3 0.38 −0.4
cg07809027 4 15007205 CPEB2 −0.1 2.08 × 10−14 NS NS
cg02215171 4 89379156 HERC5 ¶ −0.09 4.48 × 10−18 IRG 3.16 1.96
cg05883128 4 169239131 DDX60 −0.25 2.13 × 10−5 IRG 1.11 2.31
cg08099136 6 32811251 PSMB8 −0.11 1.43 × 10−4 IRG 0.76 2.51
cg00052684 6 35694245 FKBP5 § −0.16 1.65 × 10−3 −1.27 −2.77
cg05994974 7 139761087 PARP12 ‖ −0.15 6.89 × 10−5 IRG 2.26 1.86
cg14864167 8 66751182 PDE7A −0.35 1.21 × 10−9 NS NS
cg12110437 8 144098888 LY6E ♦ −0.2 3.14 × 10−9 IRG 1.28 1.23
cg03848588 9 32525008 DDX58 ♦ −0.1 4.34 × 10−4 IRG 2.89 2.59
cg06188083 10 91093005 IFIT3 ♦ −0.25 6.18 × 10−8 IRG 2.59 3.14
cg05552874 10 91153143 IFIT1 ♦ −0.26 6.01 × 10−16 IRG 2.24 2.77
cg23570810 11 315102 IFITM1 −0.27 1.43 × 10−18 IRG 2.24 3.29
cg17990365 11 319718 IFITM3 −0.16 8.78 × 10−295 IRG 2.24 2
cg08926253 11 614761 IRF7 ‖ −0.17 2.01 × 10−9 IRG 2.8 1
cg08577913 11 4415193 TRIM21 −0.1 1.74 × 10−3 IRG 1.35 0.77
cg12461141 11 5710654 TRIM22 −0.1 6.35 × 10−25 IRG 1.73 2.86
cg26811705 11 118781408 BCL9L −0.09 1.64 × 10−3 NS NS
cg19347790 12 81332050 LIN7A −0.09 1.87 × 10−4 NS −0.57
cg25800166 12 113375896 OAS3 −0.13 5.36 × 10−5 IRG 3.77 1.1
cg19371652 12 113415883 OAS2 −0.11 2.24 × 10−5 IRG 4.86 1.74
cg03753191 13 43566902 EPSTI1 ¶ −0.1 9.23 × 10−5 IRG NS NS
cg00246969 13 99159656 STK24 −0.11 6.26 × 10−6 NS 0.28
cg07839457 16 57023022 NLRC5 −0.23 6.10 × 10−6 IRG NS NS
cg23571857 17 6658898 XAF1 −0.1 1.46 × 10−8 IRG 3.14 3.05
cg23378941 17 64361956 PRKCA −0.11 6.89 × 10−5 IRG −0.48 −0.08
cg25178683 17 76976267 LGALS3BP −0.16 2.0 × 10−8 IRG 0.57 1.49
cg07573872 19 1126342 SBNO2 −0.15 2.77 × 10−3 IRG NS NS
cg07839313 19 17514600 BST2 ‖ −0.12 3.48 × 10−3 IRG NS 2.91
cg21549285 21 42799141 MX1 ∆ −0.47 6.59 × 10−13 IRG 4.05 4.64
cg19460508 22 44422195 PARVB −0.1 1.64 × 10−3 0.28 NS
cg20098015 22 50971140 ODF3B −0.21 9.88 × 10−83 IRG NS NS
Differential gene expression values come from GSE32591: kidney glomerulus and tubulointerstitium WHO class 3/4 lupus nephritis versus
control samples. NS indicates not significant FDR p-value > 0.2). * CpGs with p < 0.01 and ∆β < −0.085. † Positions are from Build 37.
‡ As defined by Interferome [37]. § SLE patients show decreased expression in both kidney tissues. ‖ Hypomethylation of this gene at the
same CpG site has been reported in SLE patients with renal involvement [12]. ¶ Hypomethylation of this gene at a different CpG site has
been reported in SLE patients with renal involvement [12]. ∆ Hypomethylation of this gene at the same CpG site has been reported in SLE
patients with and without renal involvement [12]. ♦ Hypomethylation of this gene at a different CpG site has been reported in SLE patients
with renal involvement [12].
The DM-DE genes were further analyzed in an additional pathway analysis using the
MCODE clustering algorithm and STRING networking scores. Two distinct yet related
clusters emerged (Figure 3). As expected, there was an enrichment of genes in the IFN-
inducible/pattern recognition receptor pathway. As visually represented by the colors of
the nodes and node outlines in Figure 3, all genes in this cluster were upregulated in both
active and inactive SLE patients; all of these except PARP9 were overexpressed in both
kidney tissues.
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Figure 3. MCODE clustering of hypomethylated genes showing differential expression in indepen-
dent SLE cohorts. A network scoring degree cutoff of 2, node score cutoff of 0.2, k-Core of 2, and a
max depth of 100 were applied. Node color indicates log2(FC) direction and node size is inversely
scaled with ∆β (larger nodes are more strongly hypomethylated). Edge weight is scaled by STRING
protein–protein connectivity score. All upregulated genes present in clusters were also upregulated
in inactive SLE WB samples. †, upregulated in kidney glomerulus, WHO class 3/4. ‡, upregulated in
kidney tubulointerstitium, WHO class 3/4.
The second cluster was comprised of genes involved in the nucleic acid-sensing
pathway, a primary antiviral defense in vertebrates as well as a mechanism to respond
to intracellular nucleic acids of cellular origin. There were strong links among the genes
in these two clusters as this nucleic acid response of the innate immune system results in
the production of type 1 interferon (i.e., INF-α and INF-β) and expression of interferon
stimulated genes [59]. These hypomethylated genes showed increased expression in both
active and inactive SLE patients; the lone exception observed was the reduced expression
of PRKCA in active SLE patients. As in the IFN-inducible/pattern recognition receptor
pathway, the majority of these nucleic acid-sensing pathway genes were expressed in both
kidney tissues. The gene DEAD H-box helicase 58 (DDX58), which encodes for retinoic
acid-inducible gene I (RIG-I) [60], was the central node and exhibited the strongest and
most numerous links to other genes within the cluster.
3.5. Potential Drug Targets
The DM-DE genes were analyzed for potential gene–drug interactions (Table 4). As
evidence of its potential utility, this approach identified methotrexate, a lupus therapy,
targeting EPSTI1. Twelve of the DM-DE genes are linked to drugs that are currently in
ongoing clinical trials, primarily trials related to cancer (Table 4). The drug target analysis
also identified 24 additional FDA-approved drugs linked to genes associated with the
nucleic acid-sensing or the interferon-inducible pathways. These drugs could merit careful
consideration for future clinical trials in SLE.
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Table 4. Predicted drugs targeting hypomethylated genes and associated pathways with ∆β < −0.085.
CpG * Chr Pos(bp) † Gene Mean ∆β p-Value STITCH [43] IPA ‡ DGIdb [44]
cg16526047 1 949893 ISG15 −0.11 1.28 × 10−4 Irinotecan F
cg10959651 2 7018020 RSAD2 −0.13 3.14 × 10−14 Fludarabine F
cg14126601 2 37384708 EIF2AK2 −0.1 5.55 × 10−16 Indirubin derivativeE804
cg15768138 2 219030752 CXCR1 −0.11 7.38 × 10−27 Reparixin D Reparixin D SCH-527123,Ketoprofen F
cg06981309 3 146260954 PLSCR1 −0.24 6.41 × 10−31 Wogonin G








Carfilzomib4 F Carfilzomib4 F,






cg14864167 8 66751182 PDE7A −0.35 1.21 × 10−9 Ketotifen
F,
Dyphylline F
cg12110437 8 144098888 LY6E −0.2 3.14 × 10−9 DLYE5953AD
cg06188083 10 91093005 IFIT3 −0.25 6.18 × 10−8 Imidazoles D
cg08926253 11 614761 IRF7 −0.17 2.01 × 10−9 Hesperidin D





cg00246969 13 99159656 STK24 −0.11 6.26 × 10−6 Staurosporine D










cg07839313 19 17514600 BST2 −0.12 3.48 × 10−3 Resveratrol6 D G
cg21549285 21 42799141 MX1 −0.47 6.59 × 10−13 Mitomycin C
F,
Colchicine F
cg19460508 22 44422195 PARVB −0.1 1.64 × 10−3 Lovastatin3 F Bortezomib6 F
* CpGs with p < 1 × 10−3 and ∆β < −0.085. † Positions are from Build 37. ‡ Qiagen Bioinformatics: ingenuity.com F FDA approved.
D Ongoing clinical trial or DiD G GRAS. T Known utility in lupus therapy. FW Ingenol mebutate is FDA-approved in the US but withdrawn
in the EU. Numbers in superscript are CoLTS scores and range from −16 to +11.
4. Discussion
Environmental challenges coupled with genetic susceptibility are often hypothesized
to cause the innate and adaptive immune system to become chronically active, causing
failure to recognize subsequent autoimmune disease [61]. Aging and environmental expo-
sures such as smoking, chemicals, diet, and viral pathogens predictably trigger methylation
or demethylation at CpG sites. Altered methylation of a CpG site changes the accessibility
of transcriptional elements to specific regions, which leads to regulation of gene expression.
The relationship between DNA methylation and gene expression is complex, including
being influenced by specific tissues/cells [62–64]. However, in general, DNA methylation
in promoter regions is often inversely correlated with gene expression. The above paradigm
is consistent with the results of this multi-omic study, which has demonstrated that genes
involved in the nucleic acid-sensing and interferon-inducible pathways were observed to
be hypomethylated in SLE-affected MZ twins and upregulated in independent SLE cohorts.
Despite the clear biological importance of tissue-specific methylation and gene expression,
here, the high concordance of hypomethylated genes in whole blood with increased gene
expression across a variety of tissues from multiple independent cohorts suggests a high
fidelity of the DNA methylation-gene expression relationship at these loci.
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Every epigenome-wide study of SLE to date, including this one, has identified hy-
pomethylation of multiple type I IFN-related genes. While there is no doubt that stimulation
of the type I IFN pathway is important in SLE, the mechanism by which this stimulation
occurs will be unique for each SLE patient. Interferon induction occurs due to activation of
one of several types of pattern recognition receptors, which are programmed to respond to
double-stranded DNA (dsDNA), double-stranded RNA (dsRNA), or single-stranded RNA
(ssRNA). The type of nucleic acid (NA) present will depend on the species and cell type
producing the NA. Furthermore, the NA may leak into the cytosome where its recognition
is again specific to the receptor activated. In our study, bioinformatic analysis identified
the NA-sensing pathway, with DEAD/H-Box helicase 58 (DDX58) as the central node
(Figure 3). DDX58 encodes for retinoic acid-inducible gene I (RIG-I), which recognizes
ssRNA. In contrast to Toll-like receptors (TLRs), which recognize NAs in the endosome,
RIG-I-like receptors (RLRs) interact with mitochondrial antiviral signaling protein (MAVS)
in the cytosol [65]. MAVS subsequently phosphorylates interferon regulatory factors 3
(IRF3) to stimulate type 1 IFN expression. The NA-sensing pathway generated by our
analysis also included absent in melanoma 2 (AIM2), a cytosolic dsDNA-sensing protein
that activates the inflammasome, further emphasizing the plausible role of this pathway in
initiating lupus inflammation [66,67].
The cascade of functional consequences resulting from genetic variation and unique
environmental exposures will differ for each individual SLE patient. While some SLE
patients (10–30%) will present no IFN signature [68], others will overexpress IFN through
one of the several mechanisms described above. The DM-SE gene list we prioritized may
be a useful tool in grouping SLE patients into DA receptor groups, or “endotypes” as
they have been termed by Mustelin et al. [68] Therapies targeting helicases such as RIG-I,
MAVS, or AIM2 could prove useful for SLE. One such inhibitor of RIG-I, enhancer of zeste
homolog 2 (EZH2), has been shown to play an epigenetic role in SLE and was proposed as a
therapeutic target by Tsou et al. [60]. Network analyses and public database queries of our
DM-DE genes yielded a list of genes whose products predict gene–drug interactions. The
resulting list includes methotrexate, a drug used for the treatment of lupus. The remaining
gene–drug interactions we identified merit thorough scrutiny as they could be candidates
for future trials.
Three recent studies have observed aberrant methylation of IFN genes in SLE patients
with renal involvement [12,19,22]. A summary of the literature (Additional File 2) shows
our study’s consistencies with these published findings. While hypomethylation of these
genes has been confirmed in CD4+ T cells and peripheral blood, no SLE study to date has
examined genome-wide DNA methylation in kidney biopsies. By considering differential
gene expression derived from the micro-dissected glomerulus and tubulointerstitium
kidneys in an independent cohort of SLE patients, in conjunction with the significance
of aberrant methylation in the MZ twin data, this study corroborates many of the loci
previously published as being hypomethylated in lupus nephritis patients.
The lack of any differentially methylated genes on the X chromosome is noteworthy
given the 9:1 female to male gender bias in SLE. This result is not fully explained by the fact
that older female MZ twins show a strong tendency for the same X chromosome to be inacti-
vated [69,70] as the lack of differentially methylated sites on the X chromosome in this study
is consistent with previous studies of unrelated individuals [11,15,17–21,23,52]. Jeffries
et al., using the Illumina Infinium Human Methylation27 array, did observe differential
methylation of CpGs in PCTK1, ARAF, RRAGB, and SNX12 on the X chromosome [11], but
no studies utilizing the more recent arrays replicate these findings. In our MZ twin study,
CpG sites associated with SNX12 had a minimum p-value = 0.02 (change in β = −0.04),
but none of the other three genes had p-values < 0.05. Thus, to date, methylation patterns
among genes located on the X chromosome do not appear to explain a substantial portion
of the risk of SLE.
Within this study, the genomic locations of hypomethylated CpG sites were highly
skewed toward CpG shores (0–2 kb from island) and shelves (2–4 kb from island) instead
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of islands. Here, only 5 of 59 CpG sites were in a CpG island, despite nearly one third
of the CpG sites on the Illumina HumanMethylation450 BeadChip being in a CpG island
(Supplemental Figure S2). Our findings are consistent with those of Yeung et al., who
demonstrated that most CpG sites hypomethylated in their lupus patients, when compared
to controls, were located in CpG shores [21]. These data corroborate the hypothesis that
CpG islands tend to have lower methylation rates than less dense CpG regions (e.g., shores
and shelves) and that lower density allows for greater methylation autonomy in response
to the environment, leading to increases in potential functional significance of the shores
and shelves.
There are several limitations of this multi-omics study. One limitation was the modest
sample size, as a larger sample would provide the potential to identify additional differen-
tially methylated regions and pathways. However, it is important to recognize the power
and value of a discordant MZ twin study design to reduce confounding based on genetic
and environmental background. Further, the modest sample size does not negate the
positive findings. There were only three discordant MZ twin pairs in the discovery cohort,
but we replicated these results in an independent cohort of four MZ twin pairs. Given the
number of samples, we were unable to construct and adjust for the full cell composition of
the peripheral blood samples as the limited degrees of freedom precluded the robust use
of deconvolution methods. Adjusting for latent methylation components in our analysis,
while dampening the associations slightly, still identified the same IFN signature. Further,
the collective results are supported by larger, independent case–control studies (described
in Additional File 2), and we have shown that our methylation results correlate with gene
expression in multiple cell types and tissues in independent SLE case–control studies; many
were also identified as eQTMs in a Japanese cohort of 100 healthy individuals. We recognize
that our cross-sectional study design (i.e., discovery, replication) cannot separate causality
from response to disease, but the consistency of differentially methylated regions with the
differentially expressed genes from independent gene expression studies is informative
and helps identify epigenetically modified genes and pathways that are important in SLE.
5. Conclusions
The intersection of hypomethylated genes from MZ twins and upregulated genes from
multiple independent cohorts and cell types were attributed to two distinct but integrated
biologic pathways: the nucleic acid-sensing pathway and the IFN-inducing pathway. The
source, type, and location of nucleic acids found in an SLE patient determine how and by
which receptor the NA is recognized, and ultimately which IRF is stimulated. A multi-
omics approach could allow classification of patients into different endotypes and possible
treatment groups. Informatically linking the DM-DE genes to drug therapies identified a
list of compounds that could be critically evaluated as potential candidates for future trials,
either broadly for SLE or for individuals with specific hypomethylation signatures.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/genes12121898/s1: Table S1: GEO repository datasets interrogated for differential expression
between SLE cases and controls; Table S2: Clinical characteristics of monozygotic twins discordant
for SLE; Table S3: Differential expression of hypomethylated genes in peripheral cell types from
independent SLE cohorts; Table S4: Differentially methylated probes from three monozygotic twin
pairs discordant for SLE; Figure S1: Area under the receiver operating characteristic curve (AUC)
calculated at regular intervals between 0 and −0.15 in four cell types; Figure S2: Proportions of
significantly associated CpGs (as defined in Table 1) located in islands, shores, shelves, and other
content categories; Additional File 1: Differential methylation in MZ twins discordant for SLE;
Additional File 2: Replication of CpG sites in Table 1 across published epigenome-wide SLE studies.
Author Contributions: Conceptualization, A.C.G., T.D.H., C.D.L. and P.E.L.; Acquisition of data,
A.C.G., T.D.H., J.A.K., C.D.L. and P.E.L.; Analysis and interpretation, R.D.R., H.C.A., P.B., M.D.C.,
A.C.G., S.E.H., T.D.H., A.C.L., C.D.L., P.E.L., M.C.M., P.S.R. and K.D.Z. Drafting of the manuscript,
H.C.A., A.C.G., T.D.H., C.D.L., M.C.M. and P.E.L. All authors have read and agreed to the published
version of the manuscript.
Genes 2021, 12, 1898 17 of 20
Funding: The research reported in this publication was supported by the National Institute of Arthri-
tis and Musculoskeletal and Skin Diseases under award numbers P30AR073750 and N01AR62277,
the US Department of Defense under award number W81XWH-20-1-0686, the Wake Forest School
of Medicine Center for Public Health Genomics, and research funds from CDL. AC Labonte, SE
Heuer, RD Robl, MD Catalina, PE Lipsky, and AC Grammer received financial support from the
ALR/LRI (now the Lupus Research Alliance) for drug repositioning work and from the John and
Marcia Goldman Foundation for BigData analysis of gene expression from lupus patients compared
to normal individuals.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki and approved by the Wake Forest School of Medicine Institutional Review
Board (IRB).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: All gene expression datasets are publicly available from the Gene Ex-
pression Omnibus (GEO) (Supplemental Table S1). The methylation data from the three monozygotic
twins are available upon request from the authors. Samples, including DNA, are available from the
Lupus Family Registry and Repository.
Acknowledgments: We would like to thank the Lupus Family Registry and Repository for providing
the LFRR twin samples. We also thank the Wake Forest School of Medicine Center for Public Health
Genomics for providing computational resources.
Conflicts of Interest: The authors declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential conflict of interest. The
funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in
the writing of the manuscript, or in the decision to publish the results.
References
1. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN); Harley, J.B.; Alarcón-Riquelme, M.E.; Criswell,
L.A.; Jacob, C.O.; Kimberly, R.P.; Moser, K.L.; Tsao, B.P.; Vyse, T.J.; Langefeld, C.D.; et al. Genome-wide association scan in women
with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 2008,
40, 204–210. [CrossRef] [PubMed]
2. Morris, D.L.; Sheng, Y.; Zhang, Y.; Wang, Y.-F.; Zhu, Z.; Tombleson, P.; Chen, L.; Cunninghame Graham, D.S.; Bentham, J.; Roberts,
A.L.; et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with
systemic lupus erythematosus. Nat. Genet. 2016, 48, 940–946. [CrossRef]
3. Lessard, C.J.; Sajuthi, S.; Zhao, J.; Kim, K.; Ice, J.A.; Li, H.; Ainsworth, H.; Rasmussen, A.; Kelly, J.A.; Marion, M.; et al.
Identification of a Systemic Lupus Erythematosus Risk Locus Spanning ATG16L2, FCHSD2, and P2RY2 in Koreans. Arthritis
Rheumatol. 2016, 68, 1197–1209. [CrossRef]
4. Sun, C.; Molineros, J.E.; Looger, L.L.; Zhou, X.-J.; Kim, K.; Okada, Y.; Ma, J.; Qi, Y.-Y.; Kim-Howard, X.; Motghare, P.; et al.
High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. Nat. Genet.
2016, 48, 323–330. [CrossRef]
5. Alarcón-Riquelme, M.E.; Ziegler, J.T.; Molineros, J.; Howard, T.D.; Moreno-Estrada, A.; Sánchez-Rodríguez, E.; Ainsworth, H.C.;
Ortiz-Tello, P.; Comeau, M.E.; Rasmussen, A.; et al. Genome-Wide Association Study in an Amerindian Ancestry Population
Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture. Arthritis Rheumatol. 2016, 68,
932–943. [CrossRef] [PubMed]
6. Langefeld, C.D.; Ainsworth, H.C.; Cunninghame Graham, D.S.; Kelly, J.A.; Comeau, M.E.; Marion, M.C.; Howard, T.D.; Ramos,
P.S.; Croker, J.A.; Morris, D.L.; et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat. Commun.
2017, 8, 16021. [CrossRef]
7. Deng, Y.; Tsao, B.P. Updates in Lupus Genetics. Curr. Rheumatol. Rep. 2017, 19, 68. [CrossRef] [PubMed]
8. Chen, L.; Morris, D.L.; Vyse, T.J. Genetic advances in systemic lupus erythematosus: An update. Curr. Opin. Rheumatol. 2017, 29,
423–433. [CrossRef]
9. Deapen, D.; Escalante, A.; Weinrib, L.; Horwitz, D.; Bachman, B.; Roy-Burman, P.; Walker, A.; Mack, T.M. A revised estimate of
twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992, 35, 311–318.
10. Hughes, T.; Sawalha, A.H. The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus. Arthritis Res.
Ther. 2011, 13, 245. [CrossRef]
11. Jeffries, M.A.; Dozmorov, M.; Tang, Y.; Merrill, J.T.; Wren, J.D.; Sawalha, A.H. Genome-wide DNA methylation patterns in CD4+
T cells from patients with systemic lupus erythematosus. Epigenetics 2011, 6, 593–601. [CrossRef]
12. Coit, P.; Renauer, P.; Jeffries, M.A.; Merrill, J.T.; McCune, W.J.; Maksimowicz-McKinnon, K.; Sawalha, A.H. Renal involvement in
lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells. J. Autoimmun. 2015, 61, 29–35. [CrossRef]
Genes 2021, 12, 1898 18 of 20
13. Renauer, P.; Coit, P.; Jeffries, M.A.; Merrill, J.T.; McCune, W.J.; Maksimowicz-McKinnon, K.; Sawalha, A.H. DNA methylation pat-
terns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus.
Lupus Sci. Med. 2015, 2, e000101. [CrossRef]
14. Ulff-Møller, C.J.; Asmar, F.; Liu, Y.; Svendsen, A.J.; Busato, F.; Grønbaek, K.; Tost, J.; Jacobsen, S. Twin DNA Methylation Profiling
Reveals Flare-Dependent Interferon Signature and B Cell Promoter Hypermethylation in Systemic Lupus Erythematosus. Arthritis
Rheumatol. 2018, 70, 878–890. [CrossRef]
15. Coit, P.; Jeffries, M.; Altorok, N.; Dozmorov, M.G.; Koelsch, K.A.; Wren, J.D.; Merrill, J.T.; McCune, W.J.; Sawalha, A.H. Genome-
wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve
CD4+ T cells from lupus patients. J. Autoimmun. 2013, 43, 78–84. [CrossRef]
16. Coit, P.; Ognenovski, M.; Gensterblum, E.; Maksimowicz-McKinnon, K.; Wren, J.D.; Sawalha, A.H. Ethnicity-specific epigenetic
variation in naïve CD4+ T cells and the susceptibility to autoimmunity. Epigenetics Chromatin 2015, 8, 49. [CrossRef]
17. Absher, D.M.; Li, X.; Waite, L.L.; Gibson, A.; Roberts, K.; Edberg, J.; Chatham, W.W.; Kimberly, R.P. Genome-wide DNA
methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional
changes to CD4+ T-cell populations. PLoS Genet. 2013, 9, e1003678. [CrossRef] [PubMed]
18. Coit, P.; Yalavarthi, S.; Ognenovski, M.; Zhao, W.; Hasni, S.; Wren, J.D.; Kaplan, M.J.; Sawalha, A.H. Epigenome profiling reveals
significant DNA demethylation of interferon signature genes in lupus neutrophils. J. Autoimmun. 2015, 58, 59–66. [CrossRef]
[PubMed]
19. Mok, A.; Solomon, O.; Nayak, R.R.; Coit, P.; Quach, H.L.; Nititham, J.; Sawalha, A.H.; Barcellos, L.F.; Criswell, L.A.; Chung, S.A.
Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue
hypoxia and type 1 interferon responses. Lupus Sci. Med. 2016, 3, e000183. [CrossRef]
20. Chung, S.A.; Nititham, J.; Elboudwarej, E.; Quach, H.L.; Taylor, K.E.; Barcellos, L.F.; Criswell, L.A. Genome-Wide Assessment of
Differential DNA Methylation Associated with Autoantibody Production in Systemic Lupus Erythematosus. PLoS ONE 2015, 10,
e0129813. [CrossRef] [PubMed]
21. Yeung, K.S.; Chung, B.H.-Y.; Choufani, S.; Mok, M.Y.; Wong, W.L.; Mak, C.C.Y.; Yang, W.; Lee, P.P.W.; Wong, W.H.S.; Chen,
Y.-A.; et al. Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified
Hypomethylation in Genes Related to the Type I Interferon Pathway. PLoS ONE 2017, 12, e0169553. [CrossRef]
22. Zhu, H.; Mi, W.; Luo, H.; Chen, T.; Liu, S.; Raman, I.; Zuo, X.; Li, Q.-Z. Whole-genome transcription and DNA methylation
analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus.
Arthritis Res. Ther. 2016, 18, 162. [CrossRef]
23. Imgenberg-Kreuz, J.; Carlsson Almlöf, J.; Leonard, D.; Alexsson, A.; Nordmark, G.; Eloranta, M.-L.; Rantapää-Dahlqvist, S.;
Bengtsson, A.A.; Jönsen, A.; Padyukov, L.; et al. DNA methylation mapping identifies gene regulatory effects in patients with
systemic lupus erythematosus. Ann. Rheum. Dis. 2018, 77, 736–743. [CrossRef] [PubMed]
24. Joseph, S.; George, N.I.; Green-Knox, B.; Treadwell, E.L.; Word, B.; Yim, S.; Lyn-Cook, B. Epigenome-wide association study of
peripheral blood mononuclear cells in systemic lupus erythematosus: Identifying DNA methylation signatures associated with
interferon-related genes based on ethnicity and SLEDAI. J. Autoimmun. 2019, 96, 147–157. [CrossRef]
25. Breitbach, M.E.; Ramaker, R.C.; Roberts, K.; Kimberly, R.P.; Absher, D. Population-Specific Patterns of Epigenetic Defects in the B
Cell Lineage in Patients with Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020, 72, 282–291. [CrossRef]
26. Yeung, K.S.; Lee, T.L.; Mok, M.Y.; Mak, C.C.Y.; Yang, W.; Chong, P.C.Y.; Lee, P.P.W.; Ho, M.H.K.; Choufani, S.; Lau, C.S.; et al. Cell
Lineage-specific Genome-wide DNA Methylation Analysis of Patients with Paediatric-onset Systemic Lupus Erythematosus.
Epigenetics 2019, 14, 314–351. [CrossRef] [PubMed]
27. Weeding, E.; Sawalha, A.H. Deoxyribonucleic Acid Methylation in Systemic Lupus Erythematosus: Implications for Future
Clinical Practice. Front. Immunol. 2018, 9, 875. [CrossRef] [PubMed]
28. Castillo-Fernandez, J.E.; Spector, T.D.; Bell, J.T. Epigenetics of discordant monozygotic twins: Implications for disease. Genome
Med. 2014, 6, 60. [CrossRef]
29. Javierre, B.M.; Fernandez, A.F.; Richter, J.; Al-Shahrour, F.; Martin-Subero, J.I.; Rodriguez-Ubreva, J.; Berdasco, M.; Fraga, M.F.;
O’Hanlon, T.P.; Rider, L.G.; et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus
erythematosus. Genome Res. 2010, 20, 170–179. [CrossRef] [PubMed]
30. Rakyan, V.K.; Beyan, H.; Down, T.A.; Hawa, M.I.; Maslau, S.; Aden, D.; Daunay, A.; Busato, F.; Mein, C.A.; Manfras, B.; et al.
Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011,
7, e1002300. [CrossRef]
31. Gervin, K.; Vigeland, M.D.; Mattingsdal, M.; Hammerø, M.; Nygård, H.; Olsen, A.O.; Brandt, I.; Harris, J.R.; Undlien, D.E.; Lyle,
R. DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: Identification of epigenetically
dysregulated genes. PLoS Genet. 2012, 8, e1002454. [CrossRef]
32. Häsler, R.; Feng, Z.; Bäckdahl, L.; Spehlmann, M.E.; Franke, A.; Teschendorff, A.; Rakyan, V.K.; Down, T.A.; Wilson, G.A.; Feber,
A.; et al. A functional methylome map of ulcerative colitis. Genome Res. 2012, 22, 2130–2137. [CrossRef] [PubMed]
33. Rasmussen, A.; Sevier, S.; Kelly, J.A.; Glenn, S.B.; Aberle, T.; Cooney, C.M.; Grether, A.; James, E.; Ning, J.; Tesiram, J.; et al. The
lupus family registry and repository. Rheumatology 2011, 50, 47–59. [CrossRef] [PubMed]
34. Hochberg, M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum. 1997, 40, 1725. [CrossRef] [PubMed]
Genes 2021, 12, 1898 19 of 20
35. Bombardier, C.; Gladman, D.D.; Urowitz, M.B.; Caron, D.; Chang, C.H. Derivation of the SLEDAI. A disease activity index for
lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35, 630–640. [CrossRef] [PubMed]
36. Hochberg, Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75, 800–802. [CrossRef]
37. Rusinova, I.; Forster, S.; Yu, S.; Kannan, A.; Masse, M.; Cumming, H.; Chapman, R.; Hertzog, P.J. Interferome v2.0: An updated
database of annotated interferon-regulated genes. Nucleic Acids Res. 2013, 41, D1040–D1046. [CrossRef] [PubMed]
38. Hachiya, T.; Furukawa, R.; Shiwa, Y.; Ohmomo, H.; Ono, K.; Katsuoka, F.; Nagasaki, M.; Yasuda, J.; Fuse, N.; Kinoshita, K.; et al.
Genome-wide identification of inter-individually variable DNA methylation sites improves the efficacy of epigenetic association
studies. NPJ Genom Med. 2017, 2, 11. [CrossRef] [PubMed]
39. Wu, J.; Irizarry, R.; MacDonald, J.; Gentry, J. Gcrma: Background adjustment using sequence information. R Package Version 2012,
2200, 3–10. [CrossRef]
40. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for
RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43, e47. [CrossRef] [PubMed]
41. Bader, G.D.; Hogue, C.W.V. An automated method for finding molecular complexes in large protein interaction networks. BMC
Bioinform. 2003, 4, 2. [CrossRef] [PubMed]
42. Snel, B.; Lehmann, G.; Bork, P.; Huynen, M.A. STRING: A web-server to retrieve and display the repeatedly occurring neighbour-
hood of a gene. Nucleic Acids Res. 2000, 28, 3442–3444. [CrossRef] [PubMed]
43. Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.;
Tsafou, K.P.; et al. STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015, 43,
D447–D452. [CrossRef] [PubMed]
44. Griffith, M.; Griffith, O.L.; Coffman, A.C.; Weible, J.V.; McMichael, J.F.; Spies, N.C.; Koval, J.; Das, I.; Callaway, M.B.; Eldred, J.M.;
et al. DGIdb: Mining the druggable genome. Nat. Methods 2013, 10, 1209–1210. [CrossRef] [PubMed]
45. Grammer, A.C.; Ryals, M.M.; Heuer, S.E.; Robl, R.D.; Madamanchi, S.; Davis, L.S.; Lauwerys, B.; Catalina, M.D.; Lipsky, P.E. Drug
repositioning in SLE: Crowd-sourcing, literature-mining and Big Data analysis. Lupus 2016, 25, 1150–1170. [CrossRef]
46. Mallya, M.; Campbell, R.D.; Aguado, B. Characterization of the five novel Ly-6 superfamily members encoded in the MHC, and
detection of cells expressing their potential ligands. Protein Sci. 2006, 15, 2244–2256. [CrossRef]
47. Alaridah, N.; Winqvist, N.; Håkansson, G.; Tenland, E.; Rönnholm, A.; Sturegård, E.; Björkman, P.; Godaly, G. Impaired
CXCR1-dependent oxidative defence in active tuberculosis patients. Tuberculosis 2015, 95, 744–750. [CrossRef]
48. Xu, R.; Bao, C.; Huang, H.; Lin, F.; Yuan, Y.; Wang, S.; Jin, L.; Yang, T.; Shi, M.; Zhang, Z.; et al. Low expression of CXCR1/2 on
neutrophils predicts poor survival in patients with hepatitis B virus-related acute-on-chronic liver failure. Sci. Rep. 2016, 6, 38714.
[CrossRef]
49. Almajhdi, F.N.; Al-Ahdal, M.; Abdo, A.A.; Sanai, F.M.; Al-Anazi, M.; Khalaf, N.; Viswan, N.A.; Al-Ashgar, H.; Al-Kahtani, K.;
Al-Humaidan, H.; et al. Single nucleotide polymorphisms in CXCR1 gene and its association with hepatitis B infected patients in
Saudi Arabia. Ann. Hepatol. 2013, 12, 220–227. [CrossRef]
50. Swamydas, M.; Gao, J.-L.; Break, T.J.; Johnson, M.D.; Jaeger, M.; Rodriguez, C.A.; Lim, J.K.; Green, N.M.; Collar, A.L.; Fischer,
B.G.; et al. CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival. Sci.
Transl. Med. 2016, 8, 322ra10. [CrossRef]
51. Gardiner-Garden, M.; Frommer, M. CpG islands in vertebrate genomes. J. Mol. Biol. 1987, 196, 261–282. [CrossRef]
52. Zhao, M.; Zhou, Y.; Zhu, B.; Wan, M.; Jiang, T.; Tan, Q.; Liu, Y.; Jiang, J.; Luo, S.; Tan, Y.; et al. IFI44L promoter methylation as a
blood biomarker for systemic lupus erythematosus. Ann. Rheum. Dis. 2016, 75, 1998–2006. [CrossRef]
53. Kiso, K.; Yoshifuji, H.; Oku, T.; Hikida, M.; Kitagori, K.; Hirayama, Y.; Nakajima, T.; Haga, H.; Tsuruyama, T.; Miyagawa-
Hayashino, A. Transgelin-2 is upregulated on activated B-cells and expressed in hyperplastic follicles in lupus erythematosus
patients. PLoS ONE 2017, 12, e0184738. [CrossRef]
54. Kim, H.-R.; Lee, H.-S.; Lee, K.-S.; Jung, I.D.; Kwon, M.-S.; Kim, C.-H.; Kim, S.-M.; Yoon, M.-H.; Park, Y.-M.; Lee, S.-M.; et al. An
Essential Role for TAGLN2 in Phagocytosis of Lipopolysaccharide-activated Macrophages. Sci. Rep. 2017, 7, 8731. [CrossRef]
55. Dragovich, M.A.; Mor, A. The SLAM family receptors: Potential therapeutic targets for inflammatory and autoimmune diseases.
Autoimmun. Rev. 2018, 17, 674–682. [CrossRef]
56. Li, F.J.; Won, W.J.; Becker, E.J.; Easlick, J.L.; Tabengwa, E.M.; Li, R.; Shakhmatov, M.; Honjo, K.; Burrows, P.D.; Davis, R.S. Emerging
roles for the FCRL family members in lymphocyte biology and disease. Curr. Top. Microbiol. Immunol. 2014, 382, 29–50. [CrossRef]
57. Schreeder, D.M.; Cannon, J.P.; Wu, J.; Li, R.; Shakhmatov, M.A.; Davis, R.S. Cutting edge: FcR-like 6 is an MHC class II receptor. J.
Immunol. 2010, 185, 23–27. [CrossRef] [PubMed]
58. Balada, E.; Felip, L.; Ordi-Ros, J.; Vilardell-Tarrés, M. DUSP23 is over-expressed and linked to the expression of DNMTs in CD4+
T cells from systemic lupus erythematosus patients. Clin. Exp. Immunol. 2017, 187, 242–250. [CrossRef] [PubMed]
59. Cavlar, T.; Ablasser, A.; Hornung, V. Induction of type I IFNs by intracellular DNA-sensing pathways. Immunol. Cell Biol. 2012,
90, 474–482. [CrossRef]
60. Suárez-Calvet, X.; Gallardo, E.; Nogales-Gadea, G.; Querol, L.; Navas, M.; Díaz-Manera, J.; Rojas-Garcia, R.; Illa, I. Altered
RIG-I/DDX58-mediated innate immunity in dermatomyositis. J. Pathol. 2014, 233, 258–268. [CrossRef] [PubMed]
61. Crow, M.K. Collaboration, genetic associations, and lupus erythematosus. N. Engl. J. Med. 2008, 358, 956–961. [CrossRef]
62. Ambrosi, C.; Manzo, M.; Baubec, T. Dynamics and Context-Dependent Roles of DNA Methylation. J. Mol. Biol. 2017, 429,
1459–1475. [CrossRef]
Genes 2021, 12, 1898 20 of 20
63. Crowl, J.T.; Gray, E.E.; Pestal, K.; Volkman, H.E.; Stetson, D.B. Intracellular Nucleic Acid Detection in Autoimmunity. Annu. Rev.
Immunol. 2017, 35, 313–336. [CrossRef]
64. Schübeler, D. Function and information content of DNA methylation. Nature 2015, 517, 321–326. [CrossRef] [PubMed]
65. Shrivastav, M.; Niewold, T.B. Nucleic Acid sensors and type I interferon production in systemic lupus erythematosus. Front.
Immunol. 2013, 4, 319. [CrossRef]
66. Rathinam, V.A.K.; Jiang, Z.; Waggoner, S.N.; Sharma, S.; Cole, L.E.; Waggoner, L.; Vanaja, S.K.; Monks, B.G.; Ganesan, S.; Latz, E.;
et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 2010, 11,
395–402. [CrossRef] [PubMed]
67. Man, S.M.; Karki, R.; Kanneganti, T.-D. AIM2 inflammasome in infection, cancer, and autoimmunity: Role in DNA sensing,
inflammation, and innate immunity. Eur. J. Immunol. 2016, 46, 269–280. [CrossRef]
68. Mustelin, T.; Lood, C.; Giltiay, N.V. Sources of Pathogenic Nucleic Acids in Systemic Lupus Erythematosus. Front. Immunol. 2019,
10, 1028. [CrossRef] [PubMed]
69. Christensen, K.; Kristiansen, M.; Hagen-Larsen, H.; Skytthe, A.; Bathum, L.; Jeune, B.; Andersen-Ranberg, K.; Vaupel, J.W.;
Orstavik, K.H. X-linked genetic factors regulate hematopoietic stem-cell kinetics in females. Blood 2000, 95, 2449–2451. [CrossRef]
[PubMed]
70. Huang, Q.; Parfitt, A.; Grennan, D.M.; Manolios, N. X-chromosome inactivation in monozygotic twins with systemic lupus
erythematosus. Autoimmunity 1997, 26, 85–93. [CrossRef] [PubMed]
